All Title Author
Keywords Abstract

PLOS ONE  2014 

Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells

DOI: 10.1371/journal.pone.0102197

Full-Text   Cite this paper   Add to My Lib


Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG2. Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy.


[1]  Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 62: 10–29. doi: 10.3322/caac.20138
[2]  Mittendorf EA, Peoples GE, Singletary SE (2007) Breast cancer vaccines promise for the future or pipe dream? Cancer 110: 1677–1686. doi: 10.1002/cncr.22978
[3]  Kapsenberg ML (2003) Dendritic-cell control of pathogen-driven T-cell polarization. Nat Tev Immunol 3: 984–993. doi: 10.1038/nri1246
[4]  Adams S, O'Neill DW, Bhardwaj N (2005) Recent advances in dendritic cell biology. J. Clin. Immunol 25: 87–98. doi: 10.1007/s10875-005-2814-2
[5]  Cella M, Sallusto F, Lanzavecchia A (1997) Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol 9: 10–16. doi: 10.1016/s0952-7915(97)80153-7
[6]  Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, et al. (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother 56: 1513–1537. doi: 10.1007/s00262-007-0334-z
[7]  Campbell-Anson RE, Kentor D, Wang YJ, Bushnell KM, Li Y, et al. (2008) A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology. J Immune Based Ther Vaccines 6: 1. doi: 10.1186/1476-8518-6-1
[8]  Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, et al. (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 170: 4069–4076. doi: 10.4049/jimmunol.170.8.4069
[9]  Dauer M, Schad K, Herten J, Junkmann J, Bauer C, et al. (2005) FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J Immunol Methods 302: 145–155. doi: 10.1016/j.jim.2005.05.010
[10]  Jarnjak-Jankovic S, Hammerstad H, Saeboe-Larssen S, Kvalheim G, Gaudernack G (2007) A full scale comparative study of methods for generation of functional dendritic cells for use as cancer vaccines. BMC Cancer 7: 119. doi: 10.1186/1471-2407-7-119
[11]  Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA (1998) Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282: 480–483. doi: 10.1126/science.282.5388.480
[12]  Burdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, et al. (2010) Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J Transl Med 8: 90. doi: 10.1186/1479-5876-8-90
[13]  Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, et al. (2007) Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 7: 1225–1241. doi: 10.1586/14737140.7.9.1225
[14]  Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, et al. (2007) Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 105: 277–286. doi: 10.1007/s10549-006-9457-8
[15]  Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, et al. (2009) Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immuno 257: 23–31. doi: 10.1016/j.cellimm.2009.02.002
[16]  Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, et al. (2005) Tumour-dendritic hybrid eell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23: 2367–2373. doi: 10.1016/j.vaccine.2005.01.081
[17]  Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, et al. (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J lmmunother 30: 749–761. doi: 10.1097/cji.0b013e3180de4ce8
[18]  Avigan D, Vasir B, Gong J, Borges V, Wu Z, et a1 (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10: 4699–4708. doi: 10.1158/1078-0432.ccr-04-0347
[19]  Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213–1222. doi: 10.1084/jem.192.9.1213
[20]  Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245–273. doi: 10.1146/annurev.immunol.18.1.245
[21]  Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T (2004) Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol 231: 112–125. doi: 10.1016/j.cellimm.2004.12.007
[22]  Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, et al. (2011) Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy. J Transl Med 9: 34. doi: 10.1186/1479-5876-9-34
[23]  Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, et al. (2004) Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunl 172: 6649–6657. doi: 10.4049/jimmunol.172.11.6649
[24]  Benencia F, Sprague L, McGinty J, Pate M, Muccioli M (2012) Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012: 425476. doi: 10.1155/2012/425476
[25]  Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, et al. (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30: 749–776. doi: 10.1097/cji.0b013e3180de4ce8
[26]  Trinchieri G (1998) Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16: 365–369. doi: 10.3109/08830189809043002


comments powered by Disqus

Contact Us


微信:OALib Journal